Lurbinectedin is a drug used in the treatment of small cell lung cancer (SCLC) that has shown promise in clinical trials. According to DrugPatentWatch [1], the drug has been granted orphan drug status by the FDA and is currently in phase 3 clinical trials. The site also lists the drug's patent information and expiration date.

A study published in Targeted Oncology [2] evaluated the cost-effectiveness of lurbinectedin as a second-line treatment for SCLC. The study found that lurbinectedin was a cost-effective option compared to other treatments, such as topotecan, for patients with relapsed SCLC.

Another study published in the Journal of Clinical Medicine [3] evaluated the efficacy and safety of lurbinectedin in patients with SCLC. The study found that lurbinectedin showed promising results in terms of overall response rate and progression-free survival, with manageable side effects.

While more research is needed to fully understand the effectiveness of lurbinectedin compared to other therapies, these studies suggest that it may be a promising option for the treatment of SCLC.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.targetedonc.com/view/lurbinectedin-is-cost-effective-as-a-second-line-treatment-in-sclc
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/